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ABSTRACT
Background: Coronavirus disease 2019 (COVID-19) has spread worldwide rapidly. However, the effects of
asthma, asthma medication and asthma severity on the clinical outcomes of COVID-19 have not yet been
established.
Methods: The study included 7590 de-identified patients, who were confirmed to have COVID-19 using
the severe acute respiratory syndrome coronavirus 2 RNA-PCR tests conducted up to May 15, 2020; we
used the linked-medical claims data provided by the Health Insurance Review and Assessment Service.
Asthma and asthma severity (steps suggested by the Global Initiative for Asthma) were defined using the
diagnostic code and history of asthma medication usage.
Results: Among 7590 COVID-19 patients, 218 (2.9%) had underlying asthma. The total medical cost
associated with COVID-19 patients with underlying asthma was significantly higher than that of other
patients. Mortality rate for COVID-19 patients with underlying asthma (7.8%) was significantly higher
than that of other patients (2.8%; p<0.001). However, asthma was not an independent risk factor for the
clinical outcomes of COVID-19 after adjustment, nor did asthma medication use and asthma severity
affect the clinical outcomes of COVID-19. However, use of oral short-acting β2-agonists was an
independent factor to increase the total medical cost burden. Patients with step 5 asthma showed
significant prolonged duration of admission compared to those with step 1 asthma in both univariate and
multivariate analysis.
Conclusions: Asthma led to poor outcomes of COVID-19; however, underlying asthma, use of asthma
medication and asthma severity were not independent factors for poor clinical outcomes of COVID-19,
generally.
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Introduction
Coronavirus disease 2019 (COVID-19), named by the World Health Organization (WHO), has spread
rapidly worldwide. The disease may manifest as mild upper respiratory symptoms, fever, fatigue, viral
pneumonia, acute respiratory syndrome and death [1, 2]. Coronavirus patients are usually infected through
the respiratory tract, and the cause of death is mainly due to respiratory problems [3]. Asthma is a chronic
airway inflammatory disease resulting in an imbalanced immunity of the airway [4]. Respiratory virus
infections frequently exacerbate asthma [5, 6]. We can assume that underlying asthma might affect the
clinical outcomes of COVID-19 infection, since respiratory viruses broadly increase the risk of asthma
exacerbation and death. In previous studies, underlying asthma is reported to account for 0.9–17% of
hospitalised patients with COVID-19 [1, 7, 8]. However, the importance of underlying asthma is still
overlooked in many COVID-19 studies, and there are currently no studies determining whether asthma is
a risk factor for poor prognosis of COVID-19.
Inhaled medications, especially inhaled corticosteroids (ICS), are fundamental therapeutic options for
asthma patients, and ICS are administered directly through the respiratory tract. Some asthma patients
were concerned about the use of inhaled medications during the COVID-19 pandemic owing to the risk of
respiratory infection through their inhaler device and suppression of the airway immunity system due to
the use of ICS. The worldwide asthma guideline, Global Initiative for Asthma (GINA), recommends that
asthma patients should continue taking their prescribed asthma medications, particularly ICS and oral
corticosteroids, even during the COVID-19 pandemic period. However, studies supporting this
recommendation have not been reported to date.
Korea has a national health insurance service (NHIS) that provides universal coverage for nearly all
Korean citizens. All medical costs for COVID-19 in Korea have been covered by this service. The Health
Insurance Review & Assessment Service (HIRA) has extensive linked medical claims data (including
inpatient and outpatient visits) of all the COVID-19 patients in Korea. In this study, we aimed to evaluate
the effects of asthma and asthma medication use on the prognosis of COVID-19 using the national
medical claims data for Korean patients. To the best of our knowledge, this is the first study to report on
the association between asthma and COVID-19 using national cohort data.
Materials and methods
COVID-19 patients and medical data
The Ministry of Health and Welfare of Korea and HIRA shared with researchers the world’s first
de-identified COVID-19 nationwide patient medical claims data, covering the entire Korean population,
via an online portal (accessible at https://hira-covid19.net). Among 234427 suspected COVID-19 patients,
HIRA released the de-identified list of 7590 patients, who were confirmed to have COVID-19 by the severe
acute respiratory syndrome coronavirus 2 RNA-PCR tests, conducted up to May 15, 2020 (figure 1). HIRA
provided data linked to the COVID-19 patients’ history of medical service use for the previous 3 years
(using finalised claims data from January 2017 to May 2020).
Underlying diseases and Charlson comorbidity index
We included 17 underlying diseases (myocardial infarction, congestive heart failure, peripheral vascular
disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer
disease, mild liver disease, diabetes without chronic complications, diabetes with chronic complications,
hemiplegia or paraplegia, renal disease, any malignancy, including leukaemia and lymphoma, moderate or
severe liver disease, metastatic solid tumour and AIDS/HIV infection), which are well-known underlying
conditions that affect the mortality rate and are frequently used to calculate the Charlson comorbidity
index (CCI) [9]. These underlying diseases were defined when a patient’s claims data included a related
diagnostic code at least once from January 1, 2019 to December 31, 2019. The diagnostic code was chosen
according to the suggested guideline by the HIRA (accessible at https://opendata.hira.or.kr/op/opb/
selectRfrm.do?rfrmTpCd=&searchCnd=&searchWrd=&sno=11200&pageIndex=1). The CCI, which
facilitates the prediction of disease prognosis and associated mortality, was calculated as described
previously and according to the HIRA guidelines [9].
Asthma, asthma medication and asthma severity
An asthma diagnosis was determined when patients visited the hospital (at least once) due to asthma
symptoms from January 2019 to December 2019. Furthermore, only patients who met the following
criteria during the assessment period were regarded as having asthma: 1) International Classification of
Diseases (ICD)-10 codes for asthma ( J45 and J46) as primary diagnosis or first sub-diagnosis; and
2) prescription of asthma medications on at least two occasions during outpatient visits or prescription of
asthma medication following an outpatient visit at least once and admission with treatment using systemic
corticosteroids during the assessment period. This definition of asthma was established by the HIRA
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committee according to the authoritative opinions of respiratory and allergy experts in Korea. Since then,
this definition has been used by many clinical researchers, medical statisticians and the HIRA committee
in Korea [10–12].
Asthma medication includes the following items: inhaled corticosteroids (ICS), inhaled long-acting
β2-agonists (LABA), oral LABA, patch LABA, systemic corticosteroids, leukotriene receptor antagonists
(LTRA), xanthines, inhaled short-acting β2-agonists (SABA), oral SABA and inhaled long-acting
muscarinic antagonists (LAMA). In addition, we defined asthma medication usage if it occurred within
the past year (from March 2019 to February 2020) and in the past 2 months (from January 2020 to
February 2020). All asthmatic patients were classified based on the asthma medications used for the past
year as follows. Step 1: SABA or short-acting muscarinic antagonist; step 2: ICS, LTRA or xanthine; step 3:
ICS/LABA alone, ICS+LTRA or ICS+xanthine; step 4: ICS/LABA+LAMA, ICS/LABA+LTRA or ICS/
LABA+xanthine; step 5: oral corticosteroid with a duration >90 days following some modifications of the
GINA treatment guidelines and a previous study [13].
Clinical outcomes
Mortality and admission to an intensive care unit (ICU), which are critical outcomes and represent
severity of disease, and duration of admission and total medical costs, which represent the medical and
social burden of disease, were evaluated. Reported ICD-10 diagnostic codes B342, B972, Z208, Z290, U18,
U181, Z038, Z115, U071 and U072 during the treatment period for COVID-19 were considered as clinical
outcomes. Total medical cost was defined as the sum of all medical costs for all the medical claims records
for COVID-19 during the assessment period. All medical institutions must charge the total medical costs
incurred by COVID-19 patients to the HIRA; and all the medical costs are covered by the Korean
government. Therefore, all charged costs are consistent with the total cost of care of the patient. Duration
of admission was defined as the duration from the admission date to the discharge date.
Inclusion criteria
In prescriptions from 
January 2019 to December 2019,
1) Diagnostic code for asthma (J45 and J46)
as primary diagnosis or first sub-diagnosis
2) Prescription for asthma medications
a) ≥2 occasions as outpatient visits for asthma or
b) ≥1 occasion as  outpatient visit for asthma and 
admission with treatment using systemic
corticosteroids for asthma exacerbation
Suspected COVID-19 patients
234 427 patients











or ICS/LABA with xanthine
Step 5
Oral corticosteroid











FIGURE 1 Overall study design. COVID-19: coronavirus disease 2019; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SABA:
short-acting β2-agonist; SAMA: short-acting muscarinic antagonist; ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist; LABA:
long-acting β2-agonist; LAMA: long-acting muscarinic antagonist.
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Ethics
This study was approved by the institutional review board of Severance Hospital (Seoul, Republic of Korea;
number 3-2020-0067). The requirement of obtaining informed consent was waived due to the
retrospective nature of this study.
Statistical analysis
We calculated the CCI score to evaluate comorbidities and stratified the patients according to CCI scores
of 0, 1, 2 and ⩾3 points. In addition, we used logistic regression analysis to define risk factors for clinical
outcomes and the results were adjusted for age, sex, underlying disease corresponding to each category in
the CCI score and/or asthma medications. The multicollinearity between variables was evaluated by the
variance inflation factor. The data were analysed using SAS Enterprise (version 6.1; SAS Institute, Cary,
NC, USA). p<0.05 was considered to indicate statistical significance.
Results
Clinical characteristics and prognosis of COVID-19 patients
Among 7590 COVID-19 patients, 218 (2.9%) patients had underlying asthma. Age distribution was
significantly different between the two groups (p<0.001). The CCI was significantly higher in COVID-19
patients with underlying asthma compared to that in COVID-19 patients without (p<0.001). Total
medical cost in COVID-19 patients with underlying asthma (USD 5388.1) was higher than in others
(USD 4261.0; p=0.003). Duration of admission and prevalence of admission to ICU was not significantly
different between the two groups. However, mortality rate in COVID-19 patients with underlying asthma
(7.8%) was significantly higher than others (2.8%; p<0.001).
COVID-19 patients with underlying asthma were classified according to severity of asthma. There were no
significant differences in age distribution, sex, mortality, admission to ICU and total medical cost between
the steps. However, the CCI was significantly higher and duration of admission was significantly longer in
patients with advanced steps (table 1).
Usage of asthma medication in COVID-19 patients with underlying asthma
In COVID-19 patients with underlying asthma, various asthma medications were used in the past year and
in the past 2 months, respectively, as follows. LTRA (73.4% and 66.5%) and xanthine (50.5% and 45.9%)
were the most frequently used. Following them, ICS–LABA, inhaled SABA, oral LABA and ICS alone were
also frequently prescribed (table 2).
Significant factors for mortality
Asthma was a significant factor for increased mortality rate in COVID-19 patients (OR 2.885, 95% CI
1.726–4.822) in univariate analysis. However, it was not a significant factor after adjustment for age, sex
and underlying conditions (OR 1.317, 95% CI 0.708–2.451). In the univariate analysis, only usage of
inhaled SABA or inhaled LAMA were risk factors for death. However, multivariate analysis showed that
no asthma medications affected the mortality rate. The severity of asthma showed no significant
association with mortality in both univariate and multivariate analysis (table 3).
Significant factors for ICU admission
Asthma was not a predictive factor for ICU admission in COVID-19 patients. Usage of oral SABA was a
risk factor for ICU admission in univariate analysis; however, it was not a significant factor in multivariate
analysis. In multivariate analysis, none of the asthma medications affected the risk of ICU admission. The
severity of asthma was not significantly associated with ICU admission (table 4).
Significant factors for admission duration
Among the COVID-19 patients, asthma was not a significant factor affecting the duration of admission.
Among the COVID-19 patients with underlying asthma, use of oral LABA in the past year and use of oral
LABA in the past 2 months were protective factors for admission duration in the univariate analysis.
However, they were not significant factors after adjustment. Patients with step 5 asthma showed significant
prolonged admission duration than those with step 1 asthma in both univariate and multivariate analysis
(β coefficient 19.583, 95% CI 6.011–33.155 and β coefficient 18.414, 95% CI 4.031–32.796, respectively)
(table 5).
Significant factors for total medical cost
In COVID-19 patients, asthma was a significant factor in increasing total medical cost burden (β coefficient
1384449, 95% CI 466632–2302266) in univariate analysis. However, after adjustment for age, sex and
underlying conditions, it was not a significant factor (β coefficient 524590, 95% CI −384769–1433949).
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p-value COVID-19 patients with underlying asthma
Step 1 Step 2 Step 3 Step 4 Step 5 p-value
Age years <0.001** 0.058
0–9 62 (0.8) 20 (9.2) 2 (3.9) 0 (0.0) 0 (0.0) 18 (19.2) 0 (0.0)
10–19 343 (4.7) 6 (2.8) 1 (2.0) 0 (0.0) 1 (4.2) 4 (4.3) 0 (0.0)
20–29 1833 (24.9) 19 (8.7) 8 (15.7) 3 (6.7) 3 (12.5) 5 (5.3) 0 (0.0)
30–39 758 (10.3) 18 (8.2) 4 (7.8) 3 (6.7) 1 (4.2) 10 (10.6) 0 (0.0)
40–49 983 (13.3) 25 (11.5) 7 (13.7) 5 (11.1) 4 (16.7) 8 (8.5) 1 (25.0)
50–59 1468 (19.9) 34 (15.6) 10 (19.6) 6 (13.3) 5 (20.8) 13 (13.8) 0 (0.0)
60–69 1020 (13.8) 36 (16.5) 7 (13.7) 12 (26.7) 4 (16.7) 13 (13.8) 0 (0.0)
⩾70 846 (11.5) 60 (27.5) 12 (23.5) 16 (35.6) 6 (25.0) 23 (24.5) 3 (75.0)
Sex 0.393 0.923
Male 3000 (40.7) 95 (43.6) 23 (45.1) 20 (44.4) 12 (50.0) 38 (40.4) 2 (50.0)
Female 4372 (59.3) 123 (56.4) 28 (54.9) 25 (55.6) 12 (50.0) 56 (59.6) 2 (50.0)
Charlson comorbidity index <0.001** 0.017*
0 2029 (27.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1 1726 (23.4) 48 (22.0) 12 (23.5) 3 (6.7) 5 (20.8) 28 (29.8) 0 (0.0)
2 1179 (16.0) 40 (18.4) 11 (21.6) 5 (11.1) 7 (29.2) 17 (18.1) 0 (0.0)
⩾3 2438 (33.1) 130 (59.6) 28 (54.9) 37 (82.2) 12 (50.0) 49 (52.1) 4 (100)
Prognosis
Mortality 210 (2.8) 17 (7.8) <0.001** 5 (9.8) 2 (4.4) 1 (4.2) 9 (9.6) 0 (0.0) 0.703
Admission to ICU 208 (2.8) 7 (3.2) 0.733 3 (5.9) 1 (2.2) 0 (0.0) 3 (3.2) 0 (0.0) 0.691
Duration of admission days 20.1±12.2 21.0±13.5 0.285 18.7±12.0 23.7±15.7 22.7±13.0 19.9±12.6 38.3±16.4 0.026*











Total 7372 (97.1) 218 (2.9) 51 (23.4) 45 (20.6) 24 (11.0) 94 (43.1) 4 (1.8)























TABLE 2 Use of asthma medication in coronavirus disease 2019 (COVID-19) patients with
underlying asthma
Asthma medication use
In the past year In the past 2 months
ICS alone 66 (30.3) 58 (26.6)
ICS–LABA 84 (38.5) 78 (35.8)
Inhaled LABA 0 (0.0) 0 (0.0)
Oral LABA 77 (35.3) 70 (32.1)
Patch LABA 41 (18.8) 36 (16.5)
LTRA 160 (73.4) 145 (66.5)
Inhaled SABA 83 (38.1) 75 (34.4)
Oral SABA 30 (13.8) 8 (3.7)
Xanthine 110 (50.5) 100 (45.9)
Inhaled LAMA 25 (11.5) 25 (11.5)
Data are presented as n (%). ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LTRA: leukotriene
receptor antagonist; SABA: short-acting β2-agonist; LAMA: long-acting muscarinic antagonist.
TABLE 3 Significant factors associated with mortality
Univariate Multivariate VIF
OR (95% CI) p-value OR (95% CI) p-value
Among all COVID-19 patients#
Asthma 2.885 (1.726–4.822) <0.001** 1.317 (0.708–2.451) 0.385
Among asthma patients¶
ICS alone
Past year 1.685 (0.612–4.637) 0.313 11.741 (0.765–180.151) 0.077 1.630
Past 2 months 2.059 (0.745–5.691) 0.164 17.810 (0.944–336.092) 0.055 1.822
ICS–LABA
Past year 1.462 (0.541–3.951) 0.454 1.444 (0.130–16.103) 0.765 1.425
Past 2 months 1.663 (0.615–4.502) 0.316 3.493 (0.242–50.396) 0.358 1.551
Oral LABA
Past year 0.747 (0.253–2.204) 0.597 0.890 (0.113–7.023) 0.912 1.238
Past 2 months 0.872 (0.295–2.578) 0.804 0.685 (0.085–5.508) 0.722 1.341
Patch LABA
Past year 0.252 (0.032–1.954) 0.187 0.139 (0.003–6.226) 0.309 1.583
Past 2 months 0.296 (0.038–2.309) 0.246 1.358 (0.016–112.584) 0.892 1.799
LTRA
Past year 1.194 (0.373–3.821) 0.765 1.203 (0.070–20.631) 0.899 1.278
Past 2 months 1.699 (0.534–5.408) 0.370 1.795 (0.086–37.650) 0.707 1.428
Inhaled SABA
Past year 2.505 (0.941–6.862) 0.074 1.925 (0.172–21.588) 0.595 1.686
Past 2 months 2.989 (1.089–8.208) 0.034* 1.273 (0.112–14.420) 0.846 1.924
Oral SABA
Past year 1.382 (0.372–5.125) 0.629 1.836 (0.154–21.926) 0.631 1.193
Past 2 months 1.509 (0.405–5.621) 0.540 1.626 (0.113–23.347) 0.721 1.284
Xanthine
Past year 1.114 (0.413–3.003) 0.831 0.464 (0.072–2.997) 0.420 1.208
Past 2 months 1.360 (0.504–3.667) 0.544 0.753 (0.121–4.690) 0.761 1.287
Inhaled LAMA
Past year 5.225 (1.737–15.716) 0.003* 0.515 (0.051–5.193) 0.574 1.593
Past 2 months 5.225 (1.737–15.716) 0.003* 0.371 (0.038–3.643) 0.395 1.617
Severity of asthma (reference step 1)
Step 2 0.428 (0.079–2.323) 0.325 0.068 (0.005–1.002) 0.050 1.668
Step 3 0.400 (0.044–3.627) 0.415 0.055 (0.001–2.059) 0.117 1.397
Step 4 0.974 (0.308–3.078) 0.964 0.409 (0.042–3.955) 0.440 1.759
Step 5 0.000 (0.000–999.999) 0.987 0.000 (0.000–999.999) 0.978 1.171
VIF: variance inflation factor; COVID-19: coronavirus disease 2019; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LTRA: leukotriene
receptor antagonist; SABA: short-acting β2-agonist; LAMA: long-acting muscarinic antagonist.
#: adjusted for age, sex and underlying diseases;
¶: adjusted for age, sex, underlying disease and asthma medications/severity. *: p<0.05; **: p<0.001.
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In the COVID-19 patients with underlying asthma, usage of asthma medications did not affect the total
medical cost, except for oral SABA. Usage of oral SABA in the past year (β coefficient 6258922, 95% CI
1030068–11487776) and in the past 2 months (β coefficient 5861499, 95% CI 264201–11458797) were
significant factors to increase total medical cost burden, independently, in multivariate analysis. The
severity of asthma was not significantly associated with total medical cost (table 6).
Discussion
This national study showed that COVID-19 patients with underlying asthma increase the medical cost
burden and are more susceptible to mortality than COVID-19 patients without underlying asthma.
However, asthma, asthma medication and asthma severity were not independent risk factors for clinical
outcomes of COVID-19, after adjustment for confounding factors. Only usage of oral SABA increased the
total medical cost burden independently. Patients with step 5 asthma showed longer duration of admission
compared with those with step 1 asthma. This study’s strength was that we included all the COVID-19
patients in Korea; however, the limitation was that we defined asthma patients based on the diagnosis code
and usage of asthma medication.
The prevalence of asthma among the COVID-19 patients was 2.9% in this study, which is similar to that
among the general South Korean population (1.6–2.2%) [13–15]. Underlying asthma is reported to
TABLE 4 Significant factors associated with intensive care unit admission
Univariate Multivariate VIF
OR (95% CI) p-value OR (95% CI) p-value
Among all COVID-19 patients#
Asthma 1.143 (0.531–2.457) 0.733 0.656 (0.295–1.460) 0.302
Among asthma patients¶
ICS alone
Past year 0.919 (0.174–4.861) 0.921 3.802 (0.137–105.589) 0.431 1.630
Past 2 months 1.107 (0.209–5.870) 0.905 2.387 (0.070–81.543) 0.629 1.822
ICS–LABA
Past year 0.629 (0.119–3.320) 0.585 0.384 (0.029–5.036) 0.466 1.425
Past 2 months 0.711 (0.135–3.751) 0.687 0.503 (0.046–5.451) 0.572 1.551
Oral LABA
Past year 0.725 (0.137–3.830) 0.705 0.373 (0.021–6.561) 0.500 1.238
Past 2 months 0.841 (0.159–4.446) 0.839 0.254 (0.010–6.487) 0.407 1.341
Patch LABA
Past year 0.713 (0.084–6.085) 0.757 0.061 (0.000–50.882) 0.416 1.583
Past 2 months 0.838 (0.098–7.180) 0.872 0.521 (0.000–388.916) 0.847 1.799
LTRA
Past year 0.903 (0.170–4.789) 0.905 1.588 (0.088–28.582) 0.754 1.278
Past 2 months 1.268 (0.240–6.697) 0.780 8.106 (0.309–212.62) 0.209 1.428
Inhaled SABA
Past year 0.642 (0.122–3.387) 0.602 2.385 (0.098–58.120) 0.594 1.686
Past 2 months 0.756 (0.143–3.994) 0.742 3.253 (0.083–126.978) 0.528 1.924
Oral SABA
Past year 5.112 (1.085–24.096) 0.039* 4.484 (0.317–63.484) 0.267 1.193
Past 2 months 5.581 (1.180–26.402) 0.030* 12.987 (0.472–357.078) 0.129 1.284
Xanthine
Past year 1.321 (0.289–6.045) 0.720 0.319 (0.019–5.444) 0.430 1.208
Past 2 months 1.597 (0.349–7.312) 0.546 0.564 (0.028–11.527) 0.710 1.287
Inhaled LAMA
Past year 0.000 (0.000–999.999) 0.968 0.000 (0.000–999.999) 0.904 1.593
Past 2 months 0.000 (0.000–999.999) 0.968 0.000 (0.000–999.999) 0.917 1.617
Severity of asthma (reference step 1)
Step 2 0.364 (0.036–3.626) 0.389 0.061 (0.002–1.847) 0.108 1.668
Step 3 0.000 (0.000–999.999) 0.967 0.000 (0.000–999.999) 0.945 1.397
Step 4 0.527 (0.103–2.714) 0.444 0.081 (0.004–1.581) 0.097 1.759
Step 5 0.000 (0.000–999.999) 0.987 0.000 (0.000–999.999) 0.976 1.171
VIF: variance inflation factor; COVID-19: coronavirus disease 2019; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LTRA: leukotriene
receptor antagonist; SABA: short-acting β2-agonist; LAMA: long-acting muscarinic antagonist.
#: adjusted for age, sex and underlying disease;
¶: adjusted for age, sex, underlying disease and asthma medications/severity. *: p<0.05.
https://doi.org/10.1183/13993003.02226-2020 7
PULMONARY INFECTIONS | Y.J. CHOI ET AL.
account for 0.9–17% of patients hospitalised with COVID-19 in other countries [1, 7, 8]. Some studies
have reported that the prevalence of asthma in the COVID-19 population is lower than that expected in
the general population [16, 17]; however, other studies showed that asthma was reported in up to 27% of
cases [18]. These differences may have been caused by differences in region, race and policies as well as
criteria for hospitalisation of COVID-19 patients. Additional large-scale cohort studies are required to
evaluate the prevalence of asthma in patients with COVID-19 and establish whether asthma is a risk factor
for COVID-19 infection.
In this study, underlying asthma was not an independent factor to predict poor clinical outcomes of
COVID-19 after adjustment. Age distribution and CCI were significantly different between COVID-19
patients with and without asthma. In asthma patients, very young people (aged <10 years, 9.4%) and old
people (aged ⩾60 years, 42.5%) were represented more frequently, compared to patients without asthma
(0.8% and 25.3%, respectively). The negative effects of asthma on clinical outcomes in univariate analysis
might be induced by these confounding effects (imbalanced distribution of age and CCI). After adjustment
for basic clinical factors, the negative effects of asthma on COVID-19 disappeared. However, considering
the mechanisms of asthma and COVID-19, we need further large-scale studies to confirm whether asthma
is a significant factor for clinical outcomes in COVID-19.
TABLE 5 Significant factors affecting the admission duration (days)
Univariate Multivariate VIF
β coefficient (95% CI) p-value β coefficient (95% CI) p-value
Among all COVID-19 patients#
Asthma 0.947 (−0.693–2.587) 0.258 −0.342 (−1.993–1.309) 0.685
Among asthma patients¶
ICS alone
Past year −1.385 (−5.306–2.537) 0.487 −1.083 (−6.096–3.929) 0.670 1.630
Past 2 months −2.805 (−6.869–1.260) 0.175 −3.579 (−9.083–1.925) 0.201 1.822
ICS–LABA
Past year 0.611 (−3.094–4.316) 0.746 −0.794 (−5.220–3.631) 0.724 1.425
Past 2 months 0.055 (−3.707–3.818) 0.977 −1.994 (−6.675–2.688) 0.402 1.551
Oral LABA
Past year −3.899 (−7.636–−0.162) 0.041* −3.503 (−7.703–0.696) 0.102 1.238
Past 2 months −4.248 (−8.070–−0.428) 0.030* −3.744 (−8.214–0.726) 0.100 1.341
Patch LABA
Past year 0.520 (−4.095–5.135) 0.825 4.516 (−1.292–10.324) 0.127 1.583
Past 2 months −0.948 (−5.804–3.908) 0.701 3.302 (−3.208–9.811) 0.318 1.799
LTRA
Past year −0.273 (−4.354–3.809) 0.895 0.662 (−3.952–5.277) 0.777 1.278
Past 2 months −1.812 (−5.626–2.002) 0.350 −0.620 (−5.184–3.944) 0.789 1.428
Inhaled SABA
Past year −0.573 (−4.286–3.141) 0.762 1.076 (−3.748–5.900) 0.661 1.686
Past 2 months 0.100 (−3.697–3.896) 0.959 3.915 (−1.347–9.177) 0.144 1.924
Oral SABA
Past year 4.088 (−1.119–9.295) 0.123 5.734 (0.014–11.453) 0.049* 1.193
Past 2 months 3.149 (−2.225–8.523) 0.249 4.893 (−1.210–10.997) 0.115 1.284
Xanthine
Past year 1.036 (−2.569–4.641) 0.572 −0.129 (−4.095–3.836) 0.949 1.208
Past 2 months 0.682 (−2.937–4.300) 0.711 −0.225 (−4.327–3.878) 0.914 1.287
Inhaled LAMA
Past year 0.450 (−5.210–6.111) 0.876 −3.046 (−10.192–4.099) 0.402 1.593
Past 2 months 0.450 (−5.210–6.111) 0.876 −2.431 (−9.623–4.760) 0.506 1.617
Severity of asthma (reference step 1)
Step 2 5.044 (−0.301–10.390) 0.064 4.565 (−1.127–10.258) 0.115 1.668
Step 3 4.000 (−2.470–10.470) 0.224 2.739 (−3.998–9.475) 0.424 1.397
Step 4 1.238 (−3.308–5.783) 0.592 0.976 (−3.802–5.753) 0.688 1.759
Step 5 19.583 (6.011–33.155) 0.005* 18.414 (4.031–32.796) 0.012* 1.171
VIF: variance inflation factor; COVID-19: coronavirus disease 2019; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LTRA: leukotriene
receptor antagonist; SABA: short-acting β2-agonist; LAMA: long-acting muscarinic antagonist.
#: adjusted for age, sex and underlying disease;
¶: adjusted for age, sex, underlying disease and asthma medications/severity. *: p<0.05.
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Asthma medication did not affect the clinical outcomes in this study. The usage rate of asthma medication
reported in this study is similar to that reported in general asthma patients, as described in a previous
study [10]. GINA recommends that asthma patients continue taking their prescribed asthma medications
during the COVID-19 pandemic period, because stopping asthma medication often leads to potentially
dangerous exacerbation of asthma symptoms. Among asthma medications, steroids can have dual
functions: blocking host hyperactive inflammation, including cytokine storming, and inducing the
replication of coronavirus by blocking innate immunity [19, 20]. Therefore, WHO guidance proposed that
systemic corticosteroids should be carefully used only in selected cases. In addition, some recent Japanese
studies have reported that ciclesonide, as one type of ICS, may have positive effects in treating COVID-19
[21, 22]. However, independently, this study concludes that recent use of asthma medication did not affect
clinical outcomes of COVID-19. In addition, the result of this study supports the GINA recommendation,
indirectly. Further research is needed.
In this study, use of oral SABA increased the total medical cost burden independently. SABA, as a
bronchodilator, relieves asthma symptoms; however, it has various side-effects, including tachycardia,
tremors and hypokalaemia [23, 24]. Recently, the GINA guidelines recommended that asthma patients
should not receive SABA-only treatment, because SABA-only treatment increases the risk of severe
TABLE 6 Significant factors affecting the total medical cost (Korean Won)
Univariate Multivariate VIF
β coefficient (95% CI) p-value β coefficient (95% CI) p-value
Among all COVID-19 patients#
Asthma 1384449 (466632–2302266) 0.003* 524590 (−384769–1433949) 0.258
Among asthma patients¶
ICS alone
Past year 601388 (−3023500–4226276) 0.744 2018993 (−2563742–6601729) 0.386 1.630
Past 2 months 792081 (−2976253–4560415) 0.679 1470824 (−3577161–6518809) 0.566 1.822
ICS–LABA
Past year 2234375 (−1175460–5644209) 0.198 831659 (−3214054–4877372) 0.686 1.425
Past 2 months 2179321 (−1283605–5642247) 0.216 114269 (−4179453–4407991) 0.958 1.551
Oral LABA
Past year −284193 (−3769291–3200904) 0.873 −140180 (−3979298–3698937) 0.943 1.238
Past 2 months −60004 (−3627921–3507914) 0.974 −505307 (−4605237–3594623) 0.808 1.341
Patch LABA
Past year −1480130 (−5738525–2778265) 0.494 −897283 (−6207329–4412762) 0.739 1.583
Past 2 months −1299576 (−5782702–3183550) 0.568 −1156362 (−7126157–4813433) 0.703 1.799
LTRA
Past year 92820 (−3676990–3862630) 0.961 444656 (−3774074–4663387) 0.836 1.278
Past 2 months 26391 (−3503410–3556191) 0.988 −47696 (−4233142–4137750) 0.982 1.428
Inhaled SABA
Past year 831775 (−2597167–4260718) 0.633 2163713 (−2246460–6573885) 0.334 1.686
Past 2 months 1450005 (−2051288–4951297) 0.415 2967195 (−1858526–7792917) 0.227 1.924
Oral SABA
Past year 6003767 (1235605–10771929) 0.014* 6258922 (1030068–11487776) 0.019* 1.193
Past 2 months 5634032 (712721–10555342) 0.025* 5861499 (264201–11458797) 0.036* 1.284
Xanthine
Past year 2071992 (−1248267–5392251) 0.220 648251 (−2977102–4273603) 0.725 1.208
Past 2 months 2312336 (−1016392–5641064) 0.172 725808 (−3036541–4488158) 0.704 1.287
Inhaled LAMA
Past year −749120 (−5976294–4478054) 0.778 −5247311 (−11780396–1285774) 0.115 1.593
Past 2 months −749120 (−5976294–4478054) 0.778 −5123303 (−11718897–1472292) 0.127 1.617
Severity of asthma (reference step 1)
Step 2 2259333
(−2795248–7313915)
0.379 487871 (−4839925–5815667) 0.857 1.668
Step 3 357654 (−5759943–6475251) 0.908 −786227 (−7091043–5518589) 0.806 1.397
Step 4 1555508 (−2742586–5853602) 0.476 1612493 (−2858981–6083966) 0.478 1.759
Step 5 1799480 (−11032899–14631860) 0.783 1118283 (−12342396–14578962) 0.870 1.171
VIF: variance inflation factor; COVID-19: coronavirus disease 2019; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LTRA: leukotriene
receptor antagonist; SABA: short-acting β2-agonist; LAMA: long-acting muscarinic antagonist.
#: adjusted for age, sex and underlying diseases;
¶: adjusted for age, sex, underlying disease and asthma medications/severity. *: p<0.05.
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exacerbation and asthma-related mortality, and addition of ICS significantly reduces the risk [25, 26]. Oral
SABA has been prescribed frequently in very young or old people, as a substitute for inhaled SABA.
However, it has a slower onset of action and the associated side-effects are noted more frequently
compared to those for inhaled SABA. Therefore, oral SABA may lead to increased medical cost burden in
COVID-19.
LAMA seems to be a significant factor for mortality in univariate analysis. This can be explained by the
following reasons: 1) patients who use LAMA might have COPD features; 2) patients who use LAMA
might have severe asthma because LAMA is recommended at step 4–5 based on the GINA guideline. After
adjustment for other factors, LAMA was not a significant factor to predict mortality.
COVID-19 patients with underlying asthma showed a higher total medical cost and mortality rate
compared to those without underlying asthma in this study. The airway epithelium is essential to control
inflammatory and immune responses to allergens, viruses and pollutants, which invade through the
respiratory tract [27]. However, dysfunction of the airway epithelium in asthma patients can lead to a
weakened immune defence mechanism [27, 28]. Infection from a respiratory virus frequently induces
asthma exacerbation, and it can also lead to poor clinical outcomes, and even death [5]. Autopsies of
COVID-19 infected patients showed airway inflammation and diffuse alveolar damage in pathologic
analysis [29], indicating that COVID-19 is also an airway inflammatory disease. Therefore, asthma might
negatively affect clinical outcomes in COVID-19.
The severity of asthma was not related to mortality, ICU admission and total medical cost in this study,
but it was significantly related with the duration of admission. However, because of limited evidence from
previous studies and the small number of step 5 patients in this study, additional research is thought to be
necessary to confirm these findings.
The strengths of this study are that we included almost all COVID-19 patients diagnosed in Korea, and we
included an adequate number of asthma patients. The Korean NHIS includes all medical utilisation of
almost all COVID-19 patients in Korea; and this minimises selection bias and collider bias. However, there
are some limitations of this study. First, HIRA data includes only diagnostic codes and medication use;
therefore, the definition of asthma was based on the diagnostic code and history of use of asthma
medication, while asthma was originally diagnosed based on the clinical history and objective test results.
Mild asthma patients with intermittent symptoms might have been excluded in this study. However, Korea
has a national health insurance service that covers almost all Korean citizens. Asthma patients in Korea
can visit hospitals more freely than in many other countries because of this insurance service. Hence, we
considered that the number of patients excluded due to mild asthma would not be large. Second, we could
not obtain the date of COVID-19 confirmation, real use of asthma medications and the type of medicinal
ingredients and dose of medication. Third, we could not obtain important clinical and laboratory data,
which can affect the clinical outcomes of COVID-19.
In conclusion, underlying asthma in COVID-19 patients is positively associated with medical cost burden
and mortality. However, there was no evidence of an association between asthma, asthma medication or
asthma severity and the clinical outcomes of COVID-19 after adjustment for confounding factors.
Reflecting these results, clinicians can recommend that asthma patients continue using their asthma
medication including ICS during the COVID-19 pandemic.
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